Abstract
In order to study nucleoside analog activation in the CEM cell line, a transfection protocol had to be optimized in order to silence an enzyme involved in nucleoside analog activation. Hematopoetic cell lines can be difficult to transfect with traditional lipid-based transfection, so the electroporation technique was used. Field strength, pulse length, temperature, electroporation media, siRNA concentration, among other conditions were tested in order to obtain approximately 70–80% mRNA and enzyme activity downregulation of the cytosolic enzyme deoxycytidine kinase (dCK), necessary for nucleoside analog activation. Downregulation was assessed at mRNA and enzyme activity levels. After optimizing the protocol, a microarray analysis was performed in order to investigate whether the downregulation was specific. Additionally two genes were differentially expressed besides the downregulation of dCK. These were however of unknown function. The leakage of intracellular nucleotides was also addressed in the electroporated cells since it can affect the DNA repair mechansism and the efficiency of nucleoside analogs. Three of these pools were increased compared to untreated, unelectroporated cells. The siRNA transfected cells with reduced dCK expression and activity showed reduced sensitivity to several nucleoside analogs as expected. The multidrug resistance to other drugs, as seen in nucleoside analog-induced resistant cells, was not seen with this model.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Arner ES, Eriksson S (1995) Mammalian deoxyribonucleoside kinases. Pharmacol Ther 67:155–186
Bahnson AB, Boggs SS (1990) Addition of serum to electroporated cells enhances survival and transfection efficiency. Biochem Biophys Res Commun 171:752–757
Bai L, Yamaguchi M, Tatsumi M, Kon K, Brautigam M (1998) Mechanisms responsible for resistance of sublines derived from leukemia cell lines to an antitumor agent 9-beta-D-arabinofuranosyl-2-fluoroadenine. J Cancer Res Clin Oncol 124:367–373
Bergman AM, Eijk PP, van Ruiz Haperen VW, Smid K, Veerman G, Hubeek I, van den Ijssel P, Ylstra B, Peters GJ (2005) In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. Cancer Res 65:9510–9516
Ferret E, Evrard C, Foucal A, Gervais P (2000) Volume changes of isolated human K562 leukemia cells induced by electric field pulses. Biotechnol Bioeng 67:520–528
Fox M, Boyle JM, Kinsella AR (1991) Nucleoside salvage and resistance to antimetabolite anticancer agents. Br J Cancer 64:428–436
Fyrberg A, Albertioni F, Lotfi K (2007) Cell cycle effect on the activity of deoxynucleoside analogue metabolising enzymes. Biochem Biophys Res Commun 357:847–853
Goan YG, Zhou B, Hu E, Mi S, Yen Y (1999) Overexpression of ribonucleotide reductase as a mechanism of resistance to 2, 2-difluorodeoxycytidine in the human KB cancer cell line. Cancer Res 59:4204–4207
Guittet O, Hakansson P, Voevodskaya N, Fridd S, Graslund A, Arakawa H, Nakamura Y, Thelander L (2001) Mammalian p53R2 protein forms an active ribonucleotide reductase in vitro with the R1 protein, which is expressed both in resting cells in response to DNA damage and in proliferating cells. J Biol Chem 276:40647–40651
Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4:249–264
Lembo D, Gribaudo G, Hofer A, Riera L, Cornaglia M, Mondo A, Angeretti A, Gariglio M, Thelander L, Landolfo S (2000) Expression of an altered ribonucleotide reductase activity associated with the replication of murine cytomegalovirus in quiescent fibroblasts. J Virol 74:11557–11565
Liu Y, Bergan R (2001) Improved intracellular delivery of oligonucleotides by square wave electroporation. Antisense Nucleic Acid Drug Dev 11:7–14
Lotfi K, Mansson E, Spasokoukotskaja T, Pettersson B, Liliemark J, Peterson C, Eriksson S, Albertioni F (1999) Biochemical pharmacology and resistance to 2-chloro-2′-arabino-fluoro-2′-deoxyadenosine, a novel analogue of cladribine in human leukemic cells. Clin Cancer Res 5:2438–2444
Lotfi K, Mansson E, Peterson C, Eriksson S, Albertioni F (2002) Low level of mitochondrial deoxyguanosine kinase is the dominant factor in acquired resistance to 9-beta-D-arabinofuranosylguanine cytotoxicity. Biochem Biophys Res Commun 293:1489–1496
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275
Mansson E, Flordal E, Liliemark J, Spasokoukotskaja T, Elford H, Lagercrantz S, Eriksson S, Albertioni F (2003) Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance. Biochem Pharmacol 65:237–247
Meaking WS, Edgerton J, Wharton CW, Meldrum RA (1995) Electroporation-induced damage in mammalian cell DNA. Biochim Biophys Acta 1264:357–362
Meldrum RA, Meaking WS, Wharton CW (1994) The kinetics and mechanism of repair of UV induced DNA damage in mammalian cells. The use of ‘caged’ nucleotides and electroporation to study short time course events in DNA repair. Nucleic Acids Res 22:1234–1241
Melkonyan H, Sorg C, Klempt M (1996) Electroporation efficiency in mammalian cells is increased by dimethyl sulfoxide (DMSO). Nucleic Acids Res 24:4356–4357
Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63
Nordlund P, Reichard P (2006) Ribonucleotide reductases. Annu Rev Biochem 75:681–706
Plunkett W, Grindey GB (1987) Pharmacokinetics of the 5′-triphosphates of arabinosylcytosine and 2′,2′-difluorodeoxycytidine in L1210 cells. Nucleic Acids Symp Ser 77–79
Verma NK, Dey CS (2004) RNA-mediated gene silencing: mechanisms and its therapeutic applications. J Clin Pharm Ther 29:395–404
Wang X, Zhenchuk A, Wiman KG, Albertioni F (2009) Regulation of p53R2 and its role as potential target for cancer therapy. Cancer Lett 276:1–7
Xie KC, Plunkett W (1996) Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine. Cancer Res 56:3030–3037
Yu ZW, Quinn PJ (1994) Dimethyl sulphoxide: a review of its applications in cell biology. Biosci Rep 14:259–281
Zhu C, Johansson M, Karlsson A (2000) Differential incorporation of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosylguanine into nuclear and mitochondrial DNA. FEBS Lett 474:129–132
Acknowledgments
This work was supported by grants from the Swedish Cancer Foundation, the Signe and Olof Wallentin Foundation, Capio’s Research Foundation, the Swedish Fund for Research without Animal Experiments, and the County Council of Östergötland.
Conflicts of interest
None to declare.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fyrberg, A., Lotfi, K. Optimization and evaluation of electroporation delivery of siRNA in the human leukemic CEM cell line. Cytotechnology 62, 497–507 (2010). https://doi.org/10.1007/s10616-010-9309-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10616-010-9309-6